Profound estimates Q3 revenue of $5.2-million (U.S.)

Executive Summary

• Profound Medical Corp. reports preliminary unaudited Q3 2025 revenue of $5.2 M–$5.3 M, an 84%–87% increase versus $2.8 M in Q3 2024.
• Gross margin is projected at ~72%, up from 64% a year earlier, reflecting higher installed‑base utilization of the Tulsa‑Pro system.
• The company will release full audited results after market close on Thursday, Nov 13 2025 and host a conference call at 4:30 p.m. ET to discuss the numbers and business developments.

Key Details

• Revenue Range: $5.2 M–$5.3 M (preliminary, unaudited).
• Year‑over‑Year Growth: +84% to +87% versus $2.8 M in Q3 2024.
• Gross Margin Estimate: ~72% for Q3 2025 vs. 64% in Q3 2024.
• Tulsa‑Pro Installed Base: 67 systems (up from 60 at year‑end 2024). Management expects ≥75 installations by end‑of‑year 2025.
• Capital Sales Pipeline: Described as “strong and growing,” supporting revenue outlook.
• Full Results Release: Scheduled for market close on Nov 13 2025; detailed financials to be disclosed thereafter.
• Conference Call Details:
• Date: Thursday, Nov 13 2025
• Time: 4:30 p.m. ET
• Registration link provided in the release; call will be archived on the investor website.

Notable Quotes

“During the third quarter, we achieved new highs in terms of both Tulsa‑Pro installed base growth and existing system utilization, driving record total revenues,” – Arun Menawat, CEO & Chairman.
“Our Tulsa‑Pro installed base now sits at 67 — up from 60 — and, due to our strong and growing capital sales pipeline, we continue to expect to reach at least 75 by the end of the year.” – Arun Menawat.